All In Biotech

NDA 021124 · Karo Hlthcare

Lamisil At

Terbinafine Hydrochloride · Topical

Last checked: Nov 19, 2026Latest source record: Jul 18, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Mar 17, 2000

Approved uses

1

Original approval plus efficacy supplements

Registered trials

57

14 Phase 3, 3 recruiting

FAERS reports

1,412

890 serious, 54 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 12, 2025.

Uses • cures most athlete’s foot (tinea pedis) between the toes. Effectiveness on the bottom or sides of foot is unknown. • cures most jock itch (tinea cruris) and ringworm (tinea corporis) • relieves itching, burning, cracking and scaling which accompany these conditions

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 17, 2000 Original approval · Type 8 - Partial Rx to OTC Switch ReviewLetterLabel
2 products under this application
  • LAMISIL AT · TERBINAFINE HYDROCHLORIDE 1% · SOLUTION, TOPICAL · Over-the-counter
  • LAMISIL AT · TERBINAFINE HYDROCHLORIDE 1% · SPRAY, TOPICAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Terbinafine" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective121
  • pruritus87
  • rash82
  • nausea75
  • pain67
  • fatigue66
  • dyspnoea59
  • off label use59
  • diarrhoea53
  • ageusia51
  • headache50
  • weight decreased50

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20051
20062
200730
200833
200920
201030
201126
201241
201316
201417
201558
201646
201755
201863
201980
202075
202186
2022155
2023154
2024173
2025160
202690

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 367 on PubMed

Sponsor: Karo Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.